Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP ...

Dupilumab significantly reduced gastric eosinophilic inflammation — and improved measures of endoscopic and histologic ...

For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA ...

Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American Academy of Dermatology.

Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

Sanofi raises its full-year 2026 guidance following strong Q2 results, with dupilumab surpassing €5bn in quarterly sales for ...

The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...